{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T18:44:28Z","timestamp":1772649868864,"version":"3.50.1"},"reference-count":26,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We report the outcomes of reduced-intensity allogeneic stem cell transplantation using BEAM-alemtuzumab conditioning (carmustine, etoposide, cytosine arabinoside, melphalan, and alemtuzumab 10 mg\/d on days \u20135 to \u20131) in 6 United Kingdom transplant centers. Sixty-five patients with lymphoproliferative diseases underwent sibling (n = 57) or matched unrelated donor (n = 8) transplantation. Sustained donor engraftment occurred in 60 (97%) of 62 patients. Of the 56 patients undergoing chimerism studies, 35 (63%) had full donor chimerism. Overall, 73% were in complete remission (CR) after transplantation. At a median follow-up of 1.4 years (range, 0.1-5.6 years), 37 remain alive and in CR. Acute graft-versus-host disease (GVHD) occurred in 11 (17%) of 64, grades I-II only. Estimated 1-year transplantation-related mortality (TRM) was 8% for patients undergoing first transplantation but was significantly worse for those who had previously undergone autologous transplantation. Six patients relapsed (estimated 2-year relapse risk, 20%). Histologic diagnosis (mantle cell lymphoma and high-grade non-Hodgkin lymphoma) and age at transplantation (&amp;gt; 46 years) were significantly associated with higher relapse risk and worse event-free survival. Relapse did not occur in any patient who developed acute or chronic GVHD. This study demonstrates that reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases using a BEAM-alemtuzumab preparative regimen is associated with sustained donor engraftment, a high response rate, minimal toxicity, and a low incidence of GVHD.<\/jats:p>","DOI":"10.1182\/blood-2003-05-1406","type":"journal-article","created":{"date-parts":[[2003,9,15]],"date-time":"2003-09-15T20:48:15Z","timestamp":1063658895000},"page":"428-434","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":146,"title":["BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients"],"prefix":"10.1182","volume":"103","author":[{"given":"Rowena D.","family":"Faulkner","sequence":"first","affiliation":[{"name":"From the Department of Hematology, City Hospital, Nottingham, United Kingdom; Department of Hematology, University Hospital, Birmingham, United Kingdom; Department of Hematology, Royal Free Hospital, London, United Kingdom; Department of Hematology, Kings College Hospital, London, United Kingdom; Department of Hematology, Glasgow Royal Infirmary, Glasgow, United Kingdom; and Department of Hematology, Manchester Royal Infirmary, Manchester, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Craddock","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, City Hospital, Nottingham, United Kingdom; Department of Hematology, University Hospital, Birmingham, United Kingdom; Department of Hematology, Royal Free Hospital, London, United Kingdom; Department of Hematology, Kings College Hospital, London, United Kingdom; Department of Hematology, Glasgow Royal Infirmary, Glasgow, United Kingdom; and Department of Hematology, Manchester Royal Infirmary, Manchester, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Byrne","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, City Hospital, Nottingham, United Kingdom; Department of Hematology, University Hospital, Birmingham, United Kingdom; Department of Hematology, Royal Free Hospital, London, United Kingdom; Department of Hematology, Kings College Hospital, London, United Kingdom; Department of Hematology, Glasgow Royal Infirmary, Glasgow, United Kingdom; and Department of Hematology, Manchester Royal Infirmary, Manchester, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prem","family":"Mahendra","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, City Hospital, Nottingham, United Kingdom; Department of Hematology, University Hospital, Birmingham, United Kingdom; Department of Hematology, Royal Free Hospital, London, United Kingdom; Department of Hematology, Kings College Hospital, London, United Kingdom; Department of Hematology, Glasgow Royal Infirmary, Glasgow, United Kingdom; and Department of Hematology, Manchester Royal Infirmary, Manchester, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew P.","family":"Haynes","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, City Hospital, Nottingham, United Kingdom; Department of Hematology, University Hospital, Birmingham, United Kingdom; Department of Hematology, Royal Free Hospital, London, United Kingdom; Department of Hematology, Kings College Hospital, London, United Kingdom; Department of Hematology, Glasgow Royal Infirmary, Glasgow, United Kingdom; and Department of Hematology, Manchester Royal Infirmary, Manchester, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugh G.","family":"Prentice","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, City Hospital, Nottingham, United Kingdom; Department of Hematology, University Hospital, Birmingham, United Kingdom; Department of Hematology, Royal Free Hospital, London, United Kingdom; Department of Hematology, Kings College Hospital, London, United Kingdom; Department of Hematology, Glasgow Royal Infirmary, Glasgow, United Kingdom; and Department of Hematology, Manchester Royal Infirmary, Manchester, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Potter","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, City Hospital, Nottingham, United Kingdom; Department of Hematology, University Hospital, Birmingham, United Kingdom; Department of Hematology, Royal Free Hospital, London, United Kingdom; Department of Hematology, Kings College Hospital, London, United Kingdom; Department of Hematology, Glasgow Royal Infirmary, Glasgow, United Kingdom; and Department of Hematology, Manchester Royal Infirmary, Manchester, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Pagliuca","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, City Hospital, Nottingham, United Kingdom; Department of Hematology, University Hospital, Birmingham, United Kingdom; Department of Hematology, Royal Free Hospital, London, United Kingdom; Department of Hematology, Kings College Hospital, London, United Kingdom; Department of Hematology, Glasgow Royal Infirmary, Glasgow, United Kingdom; and Department of Hematology, Manchester Royal Infirmary, Manchester, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aloysius","family":"Ho","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, City Hospital, Nottingham, United Kingdom; Department of Hematology, University Hospital, Birmingham, United Kingdom; Department of Hematology, Royal Free Hospital, London, United Kingdom; Department of Hematology, Kings College Hospital, London, United Kingdom; Department of Hematology, Glasgow Royal Infirmary, Glasgow, United Kingdom; and Department of Hematology, Manchester Royal Infirmary, Manchester, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Devereux","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, City Hospital, Nottingham, United Kingdom; Department of Hematology, University Hospital, Birmingham, United Kingdom; Department of Hematology, Royal Free Hospital, London, United Kingdom; Department of Hematology, Kings College Hospital, London, United Kingdom; Department of Hematology, Glasgow Royal Infirmary, Glasgow, United Kingdom; and Department of Hematology, Manchester Royal Infirmary, Manchester, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grant","family":"McQuaker","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, City Hospital, Nottingham, United Kingdom; Department of Hematology, University Hospital, Birmingham, United Kingdom; Department of Hematology, Royal Free Hospital, London, United Kingdom; Department of Hematology, Kings College Hospital, London, United Kingdom; Department of Hematology, Glasgow Royal Infirmary, Glasgow, United Kingdom; and Department of Hematology, Manchester Royal Infirmary, Manchester, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghulam","family":"Mufti","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, City Hospital, Nottingham, United Kingdom; Department of Hematology, University Hospital, Birmingham, United Kingdom; Department of Hematology, Royal Free Hospital, London, United Kingdom; Department of Hematology, Kings College Hospital, London, United Kingdom; Department of Hematology, Glasgow Royal Infirmary, Glasgow, United Kingdom; and Department of Hematology, Manchester Royal Infirmary, Manchester, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Liu","family":"Yin","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, City Hospital, Nottingham, United Kingdom; Department of Hematology, University Hospital, Birmingham, United Kingdom; Department of Hematology, Royal Free Hospital, London, United Kingdom; Department of Hematology, Kings College Hospital, London, United Kingdom; Department of Hematology, Glasgow Royal Infirmary, Glasgow, United Kingdom; and Department of Hematology, Manchester Royal Infirmary, Manchester, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigel H.","family":"Russell","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, City Hospital, Nottingham, United Kingdom; Department of Hematology, University Hospital, Birmingham, United Kingdom; Department of Hematology, Royal Free Hospital, London, United Kingdom; Department of Hematology, Kings College Hospital, London, United Kingdom; Department of Hematology, Glasgow Royal Infirmary, Glasgow, United Kingdom; and Department of Hematology, Manchester Royal Infirmary, Manchester, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021220171917500_REF1","doi-asserted-by":"crossref","unstructured":"Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood. 1991;77: 649-653.","DOI":"10.1182\/blood.V77.3.649.649"},{"key":"2020021220171917500_REF2","unstructured":"Van Beisen K, Sobocinski KA, Rowlings PA, et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood. 1998;92: 1832-1836."},{"key":"2020021220171917500_REF3","doi-asserted-by":"crossref","unstructured":"Ratanatharathorn V, Uberti J, Karanes C, et al. Prospective comparative trail of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood. 1994;84: 1050-1055.","DOI":"10.1182\/blood.V84.4.1050.1050"},{"key":"2020021220171917500_REF4","doi-asserted-by":"crossref","unstructured":"Tsai T, Goodman S, Saez R, et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplant. 1997;20; 859-863.","DOI":"10.1038\/sj.bmt.1700989"},{"key":"2020021220171917500_REF5","doi-asserted-by":"crossref","unstructured":"Gajewski JL, Phillips GL, Sobocinski KA, Armitage JO, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol. 1996;14: 572-578.","DOI":"10.1200\/JCO.1996.14.2.572"},{"key":"2020021220171917500_REF6","doi-asserted-by":"crossref","unstructured":"Milpeid N, Fielding AK, Pearce RM, et al. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease: European Group for Blood and Bone Marrow Transplantation. J Clin Oncol. 1996;14: 1291-1296.","DOI":"10.1200\/JCO.1996.14.4.1291"},{"key":"2020021220171917500_REF7","doi-asserted-by":"crossref","unstructured":"Akpep G, Aminder RF, Piantadosi S, et al. Long-term results of blood and bone marrow transplantation for Hodgkin's Lymphoma. J Clin Oncol. 2001;19: 4314-4321.","DOI":"10.1200\/JCO.2001.19.23.4314"},{"key":"2020021220171917500_REF8","doi-asserted-by":"crossref","unstructured":"Kottaridis PD, Milligan D, Chopra R, et al. In vivo alemtuzumab prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000;96: 2419-2425.","DOI":"10.1182\/blood.V96.7.2419"},{"key":"2020021220171917500_REF9","doi-asserted-by":"crossref","unstructured":"Khouri IF, Saliba RM, Giralt SA, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease and treatment-related mortality. Blood. 2001;15: 3595-3599.","DOI":"10.1182\/blood.V98.13.3595"},{"key":"2020021220171917500_REF10","doi-asserted-by":"crossref","unstructured":"Martino R, Cabellero D, Canals C, et al. Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. Br J Haematol. 2001;115: 653-659.","DOI":"10.1046\/j.1365-2141.2001.03153.x"},{"key":"2020021220171917500_REF11","doi-asserted-by":"crossref","unstructured":"Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using a fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998;16: 2817-2824.","DOI":"10.1200\/JCO.1998.16.8.2817"},{"key":"2020021220171917500_REF12","doi-asserted-by":"crossref","unstructured":"Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant haematological diseases. Blood. 1998;91: 756-763.","DOI":"10.1182\/blood.V91.3.756"},{"key":"2020021220171917500_REF13","doi-asserted-by":"crossref","unstructured":"Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant. 2000;25: 345-350.","DOI":"10.1038\/sj.bmt.1702392"},{"key":"2020021220171917500_REF14","doi-asserted-by":"crossref","unstructured":"Hale G, Zhang M-J, Bunjes D, et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies in bone marrow transplantation. Blood. 1998;92: 4581-4590.","DOI":"10.1182\/blood.V92.12.4581"},{"key":"2020021220171917500_REF15","doi-asserted-by":"crossref","unstructured":"Cull GM, Haynes AP, Byrne JL, et al. Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedural-related toxicity. Br J Haematol. 2000;108: 754-760.","DOI":"10.1046\/j.1365-2141.2000.01879.x"},{"key":"2020021220171917500_REF16","doi-asserted-by":"crossref","unstructured":"Cheson BD, Horning AJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol. 1999;17: 1244-1253.","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"2020021220171917500_REF17","doi-asserted-by":"crossref","unstructured":"Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989;7: 1630-1636.","DOI":"10.1200\/JCO.1989.7.11.1630"},{"key":"2020021220171917500_REF18","unstructured":"Prezprioka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15: 825-828."},{"key":"2020021220171917500_REF19","doi-asserted-by":"crossref","unstructured":"Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic haematopoietic progenitor cells with purine-analogue chemotherapy: harnessing graftversus-leukemia without myeloablative therapy. Blood. 1997;89: 4531-4536.","DOI":"10.1182\/blood.V89.12.4531"},{"key":"2020021220171917500_REF20","doi-asserted-by":"crossref","unstructured":"Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol. 1995;13: 588-595.","DOI":"10.1200\/JCO.1995.13.3.588"},{"key":"2020021220171917500_REF21","doi-asserted-by":"crossref","unstructured":"Klangsinsirikul P, Carter IG, Byrne JL, Hale G, Russell NH. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood. 2002;99: 2586-2591.","DOI":"10.1182\/blood.V99.7.2586"},{"key":"2020021220171917500_REF22","unstructured":"Rebello P, Cwynarski K, Varughese M, et al. Pharmacokinetics of Campath-1H in bone marrow transplant patients. Cytotherapy. 2001;96: 2419-2425."},{"key":"2020021220171917500_REF23","doi-asserted-by":"crossref","unstructured":"Perez-Simon JA, Kottaridis PD, Martino R, et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood. 2002;100: 3121-3127.","DOI":"10.1182\/blood-2002-03-0701"},{"key":"2020021220171917500_REF24","doi-asserted-by":"crossref","unstructured":"Marks DI, Lush R, Cavenagh J, et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning stem cell transplantation. Blood. 2002;100: 3108-3114.","DOI":"10.1182\/blood-2002-02-0506"},{"key":"2020021220171917500_REF25","doi-asserted-by":"crossref","unstructured":"Robinson S, Goldstone A, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood. 2002; 100: 4310-4316.","DOI":"10.1182\/blood-2001-11-0107"},{"key":"2020021220171917500_REF26","doi-asserted-by":"crossref","unstructured":"Vandenbergh E, Riuz de Elvira C, Loberiza FR, et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol. 2003;120: 793-800.","DOI":"10.1046\/j.1365-2141.2003.04140.x"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/2\/428\/1694728\/zh800204000428.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/2\/428\/1694728\/zh800204000428.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T20:37:51Z","timestamp":1581539871000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/103\/2\/428\/17856\/BEAMalemtuzumab-reducedintensity-allogeneic-stem"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1,15]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,1,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-05-1406","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1,15]]}}}